Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 19,179 shares, an increase of 93.0% from the July 15th total of 9,938 shares. Based on an average daily volume of 9,696 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Pharming Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHAR. EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the 2nd quarter worth $32,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group in the fourth quarter worth about $224,000. Millennium Management LLC acquired a new position in shares of Pharming Group in the fourth quarter worth about $360,000. Finally, NewEdge Advisors LLC boosted its holdings in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PHAR. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group upped their price target on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Stock Down 5.1%

Shares of NASDAQ:PHAR traded down $0.63 during mid-day trading on Friday, hitting $11.72. 20,713 shares of the company traded hands, compared to its average volume of 20,155. The firm’s 50 day simple moving average is $12.68 and its 200 day simple moving average is $14.67. The firm has a market cap of $829.54 million, a P/E ratio of 97.67 and a beta of -0.01. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. Pharming Group has a 52-week low of $9.62 and a 52-week high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. On average, equities analysts anticipate that Pharming Group will post 0.25 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.